218 related articles for article (PubMed ID: 36143844)
1. Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study.
Patoulias D; Papadopoulos C; Zografou I; Katsimardou A; Karagiannis A; Doumas M
Medicina (Kaunas); 2022 Aug; 58(9):. PubMed ID: 36143844
[No Abstract] [Full Text] [Related]
2. Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial.
Papadopoulou E; Loutradis C; Tzatzagou G; Kotsa K; Zografou I; Minopoulou I; Theodorakopoulou MP; Tsapas A; Karagiannis A; Sarafidis P
J Hypertens; 2021 Apr; 39(4):749-758. PubMed ID: 33186325
[TBL] [Abstract][Full Text] [Related]
3. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
Bosch A; Ott C; Jung S; Striepe K; Karg MV; Kannenkeril D; Dienemann T; Schmieder RE
Cardiovasc Diabetol; 2019 Mar; 18(1):44. PubMed ID: 30922297
[TBL] [Abstract][Full Text] [Related]
4. The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study.
Bechlioulis A; Markozannes G; Chionidi I; Liberopoulos E; Naka KK; Ntzani EE; Liatis S; Rizzo M; Rizos EC
J Diabetes Complications; 2023 Apr; 37(4):108436. PubMed ID: 36842186
[TBL] [Abstract][Full Text] [Related]
5. Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Papadopoulos C; Kassimis G; Fragakis N; Vassilikos V; Karagiannis A; Doumas M
Vasc Med; 2022 Oct; 27(5):433-439. PubMed ID: 35754338
[TBL] [Abstract][Full Text] [Related]
6. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.
Lunder M; Janić M; Japelj M; Juretič A; Janež A; Šabovič M
Cardiovasc Diabetol; 2018 Dec; 17(1):153. PubMed ID: 30509271
[TBL] [Abstract][Full Text] [Related]
8. Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.
Jung S; Bosch A; Kannenkeril D; Karg MV; Striepe K; Bramlage P; Ott C; Schmieder RE
Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):364-371. PubMed ID: 31816038
[TBL] [Abstract][Full Text] [Related]
9. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
Chilton R; Tikkanen I; Cannon CP; Crowe S; Woerle HJ; Broedl UC; Johansen OE
Diabetes Obes Metab; 2015 Dec; 17(12):1180-93. PubMed ID: 26343814
[TBL] [Abstract][Full Text] [Related]
10. Diabetes Mellitus, Arterial Stiffness and Cardiovascular Disease: Clinical Implications and the Influence of SGLT2i.
Lamacchia O; Sorrentino MR
Curr Vasc Pharmacol; 2021; 19(2):233-240. PubMed ID: 32183678
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
[TBL] [Abstract][Full Text] [Related]
12. Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.
Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Torimoto K; Umayahara Y; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ryomoto K; Taki H; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
Cardiovasc Diabetol; 2021 Jan; 20(1):4. PubMed ID: 33397376
[TBL] [Abstract][Full Text] [Related]
13. Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function.
Katogiannis K; Thymis J; Kousathana F; Pavlidis G; Korakas E; Kountouri A; Balampanis K; Prentza V; Kostelli G; Michalopoulou H; Tsilivarakis D; Lambadiari V; Ikonomidis I
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541121
[No Abstract] [Full Text] [Related]
14. Effect of 3-month therapy with empagliflozin on ambulatory blood pressure and arterial stiffness in patients with type 2 diabetes mellitus.
Papazafiropoulou AK; Mpoumi L; Papantoniou S; Rallatou M; Antonopoulos S; Melidonis A
Ann Afr Med; 2021; 20(2):154-155. PubMed ID: 34213486
[No Abstract] [Full Text] [Related]
15. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
Solini A; Giannini L; Seghieri M; Vitolo E; Taddei S; Ghiadoni L; Bruno RM
Cardiovasc Diabetol; 2017 Oct; 16(1):138. PubMed ID: 29061124
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus.
Papadopoulou E; Theodorakopoulou MP; Loutradis C; Tzanis G; Tzatzagou G; Kotsa K; Zografou I; Tsapas A; Karagiannis A; Sarafidis P
Am J Hypertens; 2021 Apr; 34(4):404-413. PubMed ID: 33277990
[TBL] [Abstract][Full Text] [Related]
18. Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.
Hiramatsu T; Ito H; Okumura S; Asano Y; Iguchi D; Furuta S
Diab Vasc Dis Res; 2020; 17(6):1479164120971220. PubMed ID: 33371732
[TBL] [Abstract][Full Text] [Related]
19. Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study.
Lim J; Choi YJ; Kim BS; Rhee TM; Lee HJ; Han KD; Park JB; Na JO; Kim YJ; Lee H; Kim HK
Cardiovasc Diabetol; 2023 Jul; 22(1):188. PubMed ID: 37496050
[TBL] [Abstract][Full Text] [Related]
20. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
Cherney DZ; Perkins BA; Soleymanlou N; Har R; Fagan N; Johansen OE; Woerle HJ; von Eynatten M; Broedl UC
Cardiovasc Diabetol; 2014 Jan; 13():28. PubMed ID: 24475922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
